Abstract
MYCN amplification (MNA) is the most powerful prognostic factor of neuroblastoma (NB) patients. In the high-risk non-MNA group, development of NB depends on factors other than MNA, such as genetic expression profiles, DNA methylation of tumor suppressor gene, and chromosomal loss and gain. On the other hand, many studies have demonstrated tumor-derived cell-free DNA in the serum of patients with malignancies, for a finding for molecular prognostic marker. We reviewed the clinical utility of cell-free DNA in the serum for the risk classification of patients with neuroblastoma. We discussed that detection of MNA, methylated DNA and chromosomal loss and gain in the sera. The serum based molecular analysis can provide noninvasively clinical information to determine for risk classification.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
